|
1
|
Moorkens E, Vulto AG, Huys I, Dylst P,
Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G,
Sović-Brkičić L, et al: Policies for biosimilar uptake in Europe:
An overview. PLoS One. 12:e01901472017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Farhat F, Torres A, Park W, de Lima Lopes
G, Mudad R, Ikpeazu C and Abi Aad S: The concept of biosimilars:
From characterization to evolution - A narrative review.
Oncologist. 22:1–7. 2017.PubMed/NCBI
|
|
3
|
Ratiu MP, Purcarea I, Popa F, Purcarea VL,
Purcarea TV, Lupuleasa D and Boda D: Escaping the economic turn
down through performing employees, creative leaders and growth
driver capabilities in the Romanian pharmaceutical industry.
Farmacia. 59:119–130. 2011.
|
|
4
|
European Medicines Agency: Glossary, .
http://www.ema.europa.eu/ema/index.jsp?curl=pages/document_library/landing/glossary.jsp&mid=&startLetter=AMarch
10–2018
|
|
5
|
Purcell RT and Lockey RF: Immunologic
responses to therapeutic biologic agents. J Investig Allergol Clin
Immunol. 18:335–342. 2008.PubMed/NCBI
|
|
6
|
Ahmed I, Kaspar B and Sharma U:
Biosimilars: Impact of biologic product life cycle and European
experience on the regulatory trajectory in the United States. Clin
Ther. 34:400–419. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tesser JR, Furst DE and Jacobs I:
Biosimilars and the extrapolation of indications for inflammatory
conditions. Biologics. 11:5–11. 2017.PubMed/NCBI
|
|
8
|
National Health Service, . What is a
Biosimilar Medicine? https://www.england.nhs.uk/wp-content/uploads/2015/09biosimilar-guide.pdfJune
10–2018
|
|
9
|
Food Drug Administration, . Biologics
Price Competition and Innovation Act of 2009; Meetings on User Fee
Program for Biosimilar and Interchangeable Biological Product
Applications; Request for Notification of Stakeholder Intention To
Participate. https://www.federalregister.gov/documents/2010/12/08/2010-30713/biologics-price-competition-and-innovation-act-of-2009-meetings-on-user-fee-program-for-biosimilarJune
10–2018
|
|
10
|
US Food and Drug Administration, .
Biosimilar and Interchangeable Products. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htmJune
10–2018
|
|
11
|
European Medicines Agency: Questions and
answers on generic medicines. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500012382.pdfJune
10–2018
|
|
12
|
Eleryan MG, Akhiyat S, Rengifo-Pardo M and
Ehrlich A: Biosimilars: Potential implications for clinicians. Clin
Cosmet Investig Dermatol. 9:135–142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mysler E, Pineda C, Horiuchi T, Singh E,
Mahgoub E, Coindreau J and Jacobs I: Clinical and regulatory
perspectives on biosimilar therapies and intended copies of
biologics in rheumatology. Rheumatol Int. 36:613–625. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mielke J, Jilma B, Koenig F and Jones B:
Clinical trials for authorized biosimilars in the European Union: A
systematic review. Br J Clin Pharmacol. 82:1444–1457. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ventola CL: Biosimilars part 1: Proposed
regulatory criteria for FDA approval. P T. 38:270–287.
2013.PubMed/NCBI
|
|
16
|
Vulto AG and Jaquez OA: The process
defines the product: what really matters in biosimilar design and
production? Rheumatology. 56:iv14–iv29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Crommelin DJ, Bissig M, Gouveia W and
Tredree R: Storage and handling of biopharmaceuticals: Problems and
solutions: A workshop discussion. Eur J Hosp Pharm Sci Pract.
8:89–93. 2003.
|
|
18
|
Shimasaki C: Biotechnology
Entrepreneurship: Starting, Managing, and Leading Biotech
Companies. 1st. Academic Press; Orlando, FL: pp. p3832014
|
|
19
|
Berkowitz SA, Engen JR, Mazzeo JR and
Jones GB: Analytical tools for characterizing biopharmaceuticals
and the implications for biosimilars. Nat Rev Drug Discov.
11:527–540. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
European Medicines Agency: Guideline on
comparability of biotechnology-derived medicinal products after a
change in the manufacturing process. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003935.pdfMarch
5–2018
|
|
21
|
European Medicines Agency: Guideline on
Immunogenicity Assessment of Biotechnology - Derived Therapeutic
Proteins. https://www.ema.europa.eu/documents/scientific-guideline/guideline-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-first-version_en.pdfDecember
13–2007
|
|
22
|
Patel PK, King CR and Feldman SR:
Biologics and biosimilars. J Dermatolog Treat. 26:299–302. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ramanan S and Grampp G: Drift, evolution,
and divergence in biologics and biosimilars manufacturing.
BioDrugs. 28:363–372. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schellekens H: Factors influencing the
immunogenicity of therapeutic proteins. Nephrol Dial Transplant.
20:vi3–vi9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
European Medicines Agency: Production and
Quality Control of Monoclonal Antibodies. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003444.pdfMarch
5–2018
|
|
26
|
Silva LC, Ortigosa LC and Benard G:
Anti-TNF-α agents in the treatment of immune-mediated inflammatory
diseases: Mechanisms of action and pitfalls. Immunotherapy.
2:817–833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tantu M, Belu E, Bobescu E, Armean SM,
Armean P, Constantin MM and Dominaru CD: Role of angiotensin
converting enzyme (ACE) inhibitors in hypertension and
cardiovascular protection management. Farmacia. 62:443–451.
2014.
|
|
28
|
Gheunca-Solovastru L, Vata D, Statescu L,
Constantin MM and Andrese E: Skin cancer between myth and reality,
yet ethically constrained. Rev Rom Bioet. 12:47–52. 2014.
|
|
29
|
Batani A, Brănișteanu DE, Ilie MA, Boda D,
Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary
and microvascular parameters in psoriasis vulgaris using in vivo
reflectance confocal microscopy. Exp Ther Med. 15:1241–1246.
2018.PubMed/NCBI
|
|
30
|
Căruntu C, Boda D, Căruntu A, Rotaru M,
Baderca F and Zurac S: In vivo imaging techniques for psoriatic
lesions. Rom J Morphol Embryol. 55:1191–1196. 2014.PubMed/NCBI
|
|
31
|
Caruntu C, Boda D, Dumitrascu G,
Constantin C and Neagu M: Proteomics focusing on immune markers in
psoriatic arthritis. Biomarkers Med. 9:513–528. 2015. View Article : Google Scholar
|
|
32
|
Negrei C, Arsene AL, Toderescu CD, Boda D
and Ilie M: Acitretin treatment in psoriasis may influence the cell
membrane fluidity. Farmacia. 60:767–771. 2012.
|
|
33
|
Negrei C, Caruntu C, Ginghina O,
Dragomiroiu G, Toderescu CD and Boda D: Qualitative and
quantitative determination of methotrexate polyglutamates in
erythrocytes by high performance liquid chromatography. Rev Chim.
66:607–610. 2015.
|
|
34
|
Ryan C, Sobell JM, Leonardi CL, Lynde CW,
Karunaratne M, Valdecantos WC and Hendrickson BA: Safety of
adalimumab dosed every week and every other week: Focus on patients
with hidradenitis suppurativa or psoriasis. Am J Clin Dermatol.
19:437–447. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Negrei C, Ginghina O, Caruntu C,
Dragomiroiu GB, Jinescu G and Boda D: Investigation relevance of
methotrexate polyglutamates in biological systems by high
performance liquid chromatography. Rev Chim. 66:766–768. 2015.
|
|
36
|
Boda D, Negrei C, Nicolescu F and Balalau
C: Assessment of some oxidative stress parameters in methotrexate
treated psoriasis patients. Farmacia. 62:704–710. 2014.
|
|
37
|
Kaushik VV: Review of biosimilars of
Adalimumab. J Assoc Physicians India. 65:15–21. 2017.PubMed/NCBI
|
|
38
|
Olteanu R, Constantin MM, Zota A,
Dorobantu DM, Constantin T, Serban ED, Bălănescu P, Mihele D and
Gheucă Solovăstru L: Original clinical experience and approach to
treatment study with interleukine 12/23 inhibitor in
moderate-to-severe psoriasis patients. Farmacia. 64:918–921.
2016.
|
|
39
|
Wadhwa M, Bird C, Dilger P, Rigsby P, Jia
H and Gross MEB; participants of the study, : Establishment of the
first WHO International Standard for etanercept, a TNF receptor II
Fc fusion protein: Report of an international collaborative study.
J Immunol Methods. 447:14–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Azevedo VF, Galli N, Kleinfelder A,
D'Ippolito J and Urbano PCM: Etanercept biosimilars. Rheumatol Int.
35:197–209. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Burness CB and McKeage K: Adalimumab: A
review in chronic plaque psoriasis. Drugs. 75:2119–2130. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Olteanu R, Zota A and Constantin M:
Biosimilars: An update on clinical trials (review of published and
ongoing studies). Acta Dermatovenerol Croat. 25:57–66.
2017.PubMed/NCBI
|
